Differences in the intracellular fate of free and polymer-bound doxorubicin (Q30729281)

26 June 2017

Differences in the intracellular fate of free and polymer-bound doxorubicin (English)

1 reference

26 June 2017

1 reference

6

K Ulbrich

0 references

author name string

Ondrej Hovorka

1

1 reference

26 June 2017

M St'astný

2

1 reference

26 June 2017

T Etrych

3

1 reference

26 June 2017

V Subr

4

1 reference

26 June 2017

J Strohalm

5

1 reference

26 June 2017

K Ulbrich

6

1 reference

26 June 2017

B Ríhová

7

1 reference

26 June 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

Journal of Controlled Release

26 June 2017

1 reference

26 June 2017

80

1 reference

26 June 2017

1-3

1 reference

26 June 2017

101-117

1 reference

Targetable polymeric anticancer drugs. Temporal control of drug activity

26 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Drug-polymer conjugates: potential for improved chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Antibody-targeted polymer-bound drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Targeting of human and mouse T-lymphocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Apoptosis of human tumor cells by chemotherapeutic anthracyclines is enhanced by Bax overexpression

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Time- and concentration-dependent apoptosis and necrosis induced by free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Interactions of adriamycin aglycones with mitochondria may mediate adriamycin cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Evaluation of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates as targetable drug carriers. 1. Binding, pinocytic uptake and intracellular distribution of transferrin and anti-transferrin receptor antibody conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Comparison of the liver subcellular distribution of free daunomycin and that bound to galactosamine targeted N-(2-hydroxypropyl)methacrylamide copolymers, following intravenous administration in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2802%2900016-0

7 January 2021

10.1016/S0168-3659(02)00016-0

Identifiers

DOI

1 reference

26 June 2017

1 reference